B. Riley Issues Negative Estimate for CNTA Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – B. Riley decreased their Q1 2025 earnings per share (EPS) estimates for shares of Centessa Pharmaceuticals in a research note issued to investors on Thursday, March 27th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.38) for the quarter, down from their previous forecast of ($0.36). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($2.01) EPS and FY2027 earnings at ($2.33) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04.

Several other equities analysts have also recently weighed in on CNTA. TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Morgan Stanley reissued an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $26.00.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $14.59 on Monday. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09. The firm’s 50 day simple moving average is $16.48 and its 200-day simple moving average is $16.44. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The company has a market cap of $1.92 billion, a P/E ratio of -9.54 and a beta of 1.54.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Wellington Management Group LLP lifted its position in shares of Centessa Pharmaceuticals by 14.4% in the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock worth $1,928,000 after buying an additional 14,494 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $31,000. Woodline Partners LP lifted its holdings in Centessa Pharmaceuticals by 5.7% in the 4th quarter. Woodline Partners LP now owns 545,645 shares of the company’s stock worth $9,140,000 after purchasing an additional 29,266 shares during the last quarter. Squarepoint Ops LLC boosted its position in Centessa Pharmaceuticals by 33.2% during the fourth quarter. Squarepoint Ops LLC now owns 26,806 shares of the company’s stock worth $449,000 after purchasing an additional 6,685 shares during the period. Finally, Stempoint Capital LP grew its holdings in Centessa Pharmaceuticals by 667.3% during the fourth quarter. Stempoint Capital LP now owns 641,964 shares of the company’s stock valued at $10,753,000 after purchasing an additional 558,302 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now directly owns 225,007 shares of the company’s stock, valued at $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the transaction, the general counsel now owns 118,265 shares in the company, valued at approximately $1,808,271.85. This trade represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 260,168 shares of company stock worth $4,309,568. Corporate insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.